Radiation therapy uses ionizing radiations to control and kill cancer cells. If the primary aim of ionizing radiations is to target and kill cancer cells, the beams can also impact normal tissue surrounding the tumor.
The irradiation of normal tissues can lead to irreversible side effects among 5% to 10% of the patients after the end of the treatment period.
For more than a century, research in radiobiology has demonstrated that each individual has his or her own specific tolerance threshold to ionizing radiations. As such, about 5 to 10% of patients undergoing radiation therapy are more likely than others to develop irreversible side effects.
Identifying those patients before the treatment starts is primordial in order to improve and optimize the treatment of all patients.
of patients present a hypersensitivity to ionizing radiations
Standard doses will be too high for those patients
Standard doses will be below the tolerance threshold of those patients
The success of radiation therapy lies in the radiation dose targeted at the tumor: the greater the dose is, the more chances of controlling the tumor and of healing does a patient have.
Nonetheless, the greater the dose is, the higher the risks of possible side effects. The dose cannot exceed a specific tolerance threshold at which important side effects can occur.
One of the main challenges of clinical radiobiology is to predict and assess each patient’s unique level of sensitivity to radiation therapy so as to design a tailor-made treatment.
This is precisely the objective of the tests we have developed at NovaGray.